The impact of tardive dyskinesia (TD) goes far beyond involuntary movements1,2

75% of patients reported that TD severely impacted them socially, physically, and psychologically3

3-year longitudinal registry and study ongoing to assess the impact of TD and real-world treatment patterns and outcomes: learn more. The Phase 4, multicenter, prospective, observational 2-part study is the largest-ever of its kind for TD and will collect information from both patients and physicians.

In a survey of 269 patients, the impact of TD on daily living was substantial—even for patients with self-assessed mild/moderate symptoms4

Psychological/psychiatric factors3

  • Effect on underlying condition
  • Compliance with treatment
  • Development of other psychiatric symptoms (eg, anxiety)
  • Other negative emotions

Social factors2,5

  • Effect on relationships
  • Social isolation
  • Withdrawal

Physical factors2,6,7

  • Speech impairment
  • Difficulty eating
  • Reduced fine motor function
  • Impaired gait/balance

Vocational factors8

  • Inability or reduced ability to perform job duties
  • Challenges with employment
  • Avoidance of people

TD symptoms can disrupt the treatment of your patient’s underlying condition4,8

In the same survey, patients with TD reported that their involuntary movements interfered with adherence to psychiatric treatment4:


Skipped doses of antipsychotic medication or took less than doctor instructed


Stopped taking antipsychotic medication altogether


Stopped going to the doctor to treat their underlying condition


Advised someone else not to take an antipsychotic medication

Patient characteristics in the TD Impact Study
  • Survey included patients with major depressive disorder, schizophrenia or schizoaffective disorder, and bipolar disorder4
  • Patients’ TD symptoms ranged from mild to very severe4
  • Patient population spanned a diverse range of races/ethnicities4

No clinical trials have been conducted to demonstrate that treating TD affects the outcomes on this page.

TD Talks Logo

Watch Amber Hoberg, PMHNP-BC, discuss the importance of assessing and managing TD

REFERENCES: 1. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176. 2. Yassa R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989;80(1):64-67. 3. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 4. Jain R, Ayyagari R, King S, Edwards GG, Wilhelm A, Leo S. Impact of tardive dyskinesia on physical, psychological, and social aspects of patient lives: a survey of patients and caregivers in the United States. Presented at: Psych Congress 2021; October 29–November 1, 2021; San Antonio, TX. 5. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580-1588. 6. Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr. 2018;23(6):370-377. 7. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71 8. Jackson R, Brams MN, Citrome L, et al. Assessment of the impact of tardive dyskinesia in clinical practice: consensus panel recommendations. Neuropsychiatr Dis Treat. 2021;17:1589-1597.